|
| 产品描述 |
| A novel potent and selective, orally active URAT1 inhibitor with Ki of 57 nM, 130 and 42-fold selectivity over OAT1 and OAT3, respectively; increases the fractional excretion of urinary uric acid, and reduces plasma uric acid more effectively in vivo, compared with benzbromarone, also shows lower in vitro potential for mechanisms causing the hepatotoxicity induced by benzbromarone. |
| 化学结构 |
 |
| 化学名称 |
| (3,5-dibromo-4-hydroxyphenyl)(2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazin-4-yl)methanone |
| 基本信息 |
产品编号:XM775
产品名称:UR-1102 (Epaminurad)
别名:UR1102, Epaminurad
CAS#:1198153-15-9
分子式:C14H10Br2N2O3
精确分子量:414.053
分子量:414.05
纯度:>98%
|
| 物化性质 |
外观: 固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
